Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators—842
View Patent ↗Compounds of Formula (I) wherein R 1 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
1. A compound according to Formula I:
wherein
R 1 is halo or C 1-3 haloalkoxyl;
Q is
and
R 2 is hydrogen or C 1-3 alkyl, or a pharmaceutically acceptable salt, hydrate, optical isomer, or combination thereof.
2. A compound according to claim 1 , wherein R 1 is chloro or trifluoromethoxyl or a pharmaceutically acceptable salt, hydrate, or optical isomer thereof.
3. A compound according to claim 2 , wherein R 1 is trifluoromethoxyl or a pharmaceutically acceptable salt, hydrate, or optical isomer thereof.
4. A compound according to claim 1 , wherein Q is
or a pharmaceutically acceptable salt, hydrate, or optical isomer thereof.
5. A compound according to claim 4 , wherein Q is
and R 2 is H or a pharmaceutically acceptable salt, hydrate, or optical isomer thereof.
6. A compound according to claim 1 , wherein R 1 is chloro or trifluoromethoxyl and Q is
or a pharmaceutically acceptable salt, hydrate, or optical isomer thereof.
7. A compound according to claim 6 , wherein R 1 is trifluoromethoxyl and Q is
or a pharmaceutically acceptable salt, hydrate, or optical isomer thereof.
8. A compound according to claim 1 , wherein R 1 is chloro or trifluoromethoxyl, Q is
wherein R 2 is H, or a pharmaceutically acceptable salt, hydrate, or optical isomer thereof.
9. A compound according to claim 1 , wherein R 1 is chloro or trifluoromethoxyl and Q is
or a pharmaceutically acceptable salt, hydrate, or optical isomer thereof.
10. A compound according to claim 1 selected from:
7-methyl-5-(3-piperazin-1-ylmethyl-[1,2,4]oxadiazol-5-yl)-2-(4-trifluoromethoxy benzyl)-2,3-dihydroisoindol-1-one;
2-(4-chloro-benzyl)-5-[3-(2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl)-[1,2,4]oxadiazol-5-yl]-7-methyl-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-[3-(3-methyl-piperazin-1-ylmethyl)-[1,2,4]oxadiazol-5-yl]-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-(3-piperazin-1-ylmethyl-[1,2,4]oxadiazol-5-yl)-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-[3-(2-methyl-piperazin-1-ylmethyl)-[1,2,4]oxadiazol-5-yl]-2,3-dihydro-isoindol-1-one, or
2-(4-chloro-benzyl)-7-methyl-5-[3-(2-methyl-piperazin-1-ylmethyl)-[1,2,4]oxadiazol-5-yl]-2,3-dihydro-isoindol-1-one.
11. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.
12. A pharmaceutical composition comprising a compound according to claim 10 and a pharmaceutically acceptable carrier or excipient.
13. A method for the treatment of schizophrenia, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 12 .